Compare EPR Properties (EPR) vs Eli Lilly And Co (LLY) Price & Performance

EPR Properties trades at $60.32, down 0.13% recently, with a bearish technical signal from moving averages and oscillators. The company reported strong Q2 2026 results, beating FFO estimates, and raised full-year guidance. Revenue grew to $699 million in 2026, though net income dipped to $263 million. Analysts maintain a consensus price target of $65.30, with 27% buy ratings, but technical indicators suggest near-term pressure.

The outlook is mixed: fundamental strength from dividend growth and acquisitions supports long-term value, but technical bearishness and elevated valuation ratios pose risks. Investors should weigh the 6% dividend yield against potential volatility from interest rate sensitivity and market sentiment shifts.

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.